HRS2300 + trametinib

**HRS2300 + trametinib** is a combination of two pharmaceutical agents: HRS2300 and trametinib. **Trametinib** is a small molecule inhibitor of MEK1/2, approved for the treatment of various tumors with BRAF V600 mutations, typically given orally. **HRS2300** is a less-known code name and details about its structure, mechanism, or development status are not readily available in authoritative public sources as of September 2025. No specific information about the mechanism of HRS2300 was found in the major literature or regulatory agencies, and there is no evidence the combination has been clinically evaluated or approved. Trametinib is a kinase inhibitor that disrupts aberrant signaling in the MAPK pathway, usually combined in practice with BRAF inhibitors like dabrafenib for enhanced clinical efficacy in BRAF-mutant cancers[7][5][4][6][1].